Physician profile
Phyllis C Zee
NPI 1255418927
$214,167.74
in general payments reported to CMS, 2019-2025
12 companies · $52K in 2025
The $52K reported for 2025 was more than what 96% of Sleep Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $337).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $29K · 2021: $25K · 2022: $12K · 2023: $28K · 2024: $26K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $89K · Travel and Lodging: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,225 · Food and Beverage: $1,376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $89,304.25 |
| Travel and Lodging | $10,147.69 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,225.00 |
| Food and Beverage | $1,376.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $74,434.07 | 2019-2025 | |
| Eisai INC. | $36,054.62 | 2019-2023 | |
| Eisai Co., Ltd. | $31,920.86 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $18,184.17 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16,232.21 | 2021-2025 | |
| Idorsia Pharmaceuticals US INC | $14,300.86 | 2022-2023 | Quviviq |
| Harmony Biosciences LLC | $10,897.50 | 2020-2025 | Wakix |
| Merck Sharp & Dohme LLC | $5,790.86 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $4,852.59 | 2025 | Lumryz |
| Itamar Medical INC | $1,500.00 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phyllis Zee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.